# LIBRETTO-121 (NCT03899792)

> A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03899792
- Phase: PHASE1, PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Eli Lilly and Company
- Conditions: Medullary Thyroid Cancer; Infantile Myofibromatosis; Infantile Fibrosarcoma; Papillary Thyroid Cancer; Soft Tissue Sarcoma
- Interventions: Selpercatinib
- Enrollment: 36
- Primary outcome: Phase 1: Number of Participants With Dose Limiting Toxicities (DLTs)
- Primary outcome: Phase 2: Percentage of Participants With Overall Response Rate (ORR) in Study

## Commentary we found

- Podcasts: 2
- YouTube: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=libretto-121-nct03899792